
A UK pharma firm has launched a cut-price version of Pfizer’s Lyrica along with a bespoke supply chain to ensure …

Teva Pharmaceutical Industries has confirmed the appointment of Timothy Wright to its executive leadership team to head up business development, …

Takeda has licensed the exclusive rights to use ImmunoGen’s popular antibody-drug conjugate (ADC) technology to develop new cancer drugs. The …

Novo Nordisk’s obesity drug Saxenda has been approved by the European Commission for use across the EU. This approval follows …
Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …

Pfizer and Eli Lilly will resume Phase III clinical trials of tanezumab following the FDA lifting a ban on trials …

Merck KGaA is to promote its deputy chief executive Stefan Oschmann to replace Karl-Ludwig Kley in the top job next …

The European Medicines Agency has elected Dr Christa Wirthumer-Hoche, the head of the Austrian Medicines and Medical Devices Agency, as …

AbbVie is investing $30 million to expand one of its sites in Puerto Rico, and is also backing a promising …

Google has filed a patent application for a new cancer-fighting wearable device which it says targets the cells in the …
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …

Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …

Maetrics has confirmed that Steve Cottrell, previously its vice president of sales, will now assume the role of president at …

Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …

Eli Lilly and Korean-based pharma firm Hanmi have entered a collaboration agreement to develop and commercialise an immunological therapy. The …

Senior NHS figures have hit out at Chancellor George Osborne’s failure to lay out any specific plans concerning the future …

An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …

Ireland, Dublin-based pharma firm Actavis has added former Allergan members Michael Gallagher and Dr Peter McDonnell to its board of …

The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …

The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …